Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome

Gynecologic and Obstetric Investigation

Volumn 50, Issue 3, 2000, Pages 186-188

  Ohata, Yorie ^a   Harada, Tasuku ^a   Ito, Masayuki ^a   Yoshida, Souichi ^a   Iwabe, Tomio ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Chorionic gonadotropin, human; Coasting; In vitro fertilization and embryo transfer; Ovarian hyperstimulation syndrome; Polycystic ovary

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRAUTERINE INSEMINATION; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; PRIORITY JOURNAL;

EID: 0033803013     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010307     Document Type: Article

References (12)

1. Smitz J, Camus M, Devrocy P, Erard P, Wisanto A, Van Steirteghem AC: Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for invitro fertilization. Hum Reprod 1990;5:933-937.
2. Navot D, Bergh PA, Laufer N: Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 1992;58:249-261.
3. Sher G, Zouves C, Feinman M, Maassarani G: 'Prolonged coas,ting': An effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 1995;10:3107-3109.
4. Chen CD, Chen SU, Wu MY, Ho HN, Yang JH, Yang YS: Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertil Steril 1997;68: 287-291.
5. Harada T, Katagiri C, Takao N, Toda T, Mio Y, Terakawa N: Altering the timing of human chorionic gonadotropin injection according to serum progesterone (P) concentrations improves embryo quality in cycles with subtle P rise. Fertil Steril 1996;65:594-597.
6. Demetrios M, Michael MA, Selwyn PO, Susan ML, Joseph FM, Spyros NP: Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: Cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am J Obstet Gynecol 1995;172: 1518-1525.
7. Wada I, Matson PL, Trou SA, Morroll DR, Hunt L, Lieberman BA: Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? Br J Obstet Gynaecol 1993;100:265-269.
8. Lee A, Christenson LK, Patton PE, Burry KA, Stouffer RL: Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil Steril 1997;68:305-311.
9. Elchalal U, Schenker JG: The pathophysiology of ovarian hyperstimulation syndrome - Views and ideas. Hum Reprod 1997;12:1129-1137.
10. Neulen J, Yan Z, Raczek S, Weindel K, Kech C, Weich HA, Marme D, Breckwoldt M: Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/ vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 80:1967-1971.
11. Benadiva CA, Davis O, Kligman I, Moomjy M, Liu HC, Rosenwaks Z: Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997;67:724-727.
12. Dhont M, Van der Straeten F, De Sutter P: Prevention of severe ovarian hyperstimulation by coasting. Fertil Steril 1998;70:847-850.